Research Progress on E3 Ubiquitin Ligases in the Cervical Cancer

doi:10.12280/gjfckx.20250173

Abstract

Abstract:

Cervical cancer is the common gynecological malignancy with a relatively high incidence and mortality rate, and it shows a trend of younger onset, seriously endangering women′s health. Persistent infection with high-risk human papilloma virus (HPV) is the key and initiating factor for the occurrence and development of cervical cancer. Although surgery, radiotherapy, and chemotherapy have greatly improved the prognosis of cervical cancer patients, the survival rate of advanced cervical cancer remains unsatisfactory. Therefore, finding targeted therapeutic targets can provide new methods for clinical diagnosis and treatment. As a key enzyme in the ubiquitination cascade reaction, E3 ubiquitin ligases is responsible for tagging ubiquitin molecules onto target proteins, thereby regulating their biological function. E3 ubiquitin ligases can be mainly divided into three major categories: RING-type, HECT-type, and RBR-type. They can block the persistent HPV infection state and inhibit the progression of cervical cancer through mechanisms such as regulating the proliferation of cervical cancer cells, participating in cell migration and invasion, affecting the cell cycle, regulating the sensitivity to radiotherapy and chemotherapy, and mediating immune evasion. In terms of application, using proteasome inhibitors or directly targeting E3 ubiquitin ligases can delay the progression of the disease. In recent years, newly developed proteolysis, targeting chimeras and molecular glues also show broad prospects in the field of treatment.

Key words: Ubiquitination, Ubiquitin-protein ligases, Uterine cervical neoplasms, Therapy, Human papilloma virus

LIAN Si-han, HAN Meng-fei, WANG Yu-jue, ZHAO Lin-yan, HU Yan. Research Progress on E3 Ubiquitin Ligases in the Cervical Cancer[J]. Journal of International Obstetrics and Gynecology, 2025, 52(3): 319-325.

References 39

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263. doi: 10.3322/caac.21834.
[2]	Tewari KS. Cervical Cancer[J]. N Engl J Med, 2025, 392(1):56-71. doi: 10.1056/NEJMra2404457.
[3]	Li XM, Zhao ZY, Yu X, et al. Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy[J]. Exp Hematol Oncol, 2023, 12(1):34. doi: 10.1186/s40164-023-00394-2.
[4]	Sampson C, Wang Q, Otkur W, et al. The roles of E3 ubiquitin ligases in cancer progression and targeted therapy[J]. Clin Transl Med, 2023, 13(3):e1204. doi: 10.1002/ctm2.1204. pmid: 36881608
[5]	Gao L, Zhang W, Shi XH, et al. The mechanism of linear ubiquitination in regulating cell death and correlative diseases[J]. Cell Death Dis, 2023, 14(10):659. doi: 10.1038/s41419-023-06183-3. pmid: 37813853
[6]	Morreale FE, Walden H. Types of Ubiquitin Ligases[J]. Cell, 2016, 165(1):248-248.e1. doi: 10.1016/j.cell.2016.03.003. pmid: 27015313
[7]	Dewson G, Eichhorn P, Komander D. Deubiquitinases in cancer[J]. Nat Rev Cancer, 2023, 23(12):842-862. doi: 10.1038/s41568-023-00633-y. pmid: 37935888
[8]	Spano D, Catara G. Targeting the Ubiquitin-Proteasome System and Recent Advances in Cancer Therapy[J]. Cells, 2023, 13(1):29. doi: 10.3390/cells13010029.
[9]	Zou Q, Liu M, Liu K, et al. E3 ubiquitin ligases in cancer stem cells: key regulators of cancer hallmarks and novel therapeutic opportunities[J]. Cell Oncol(Dordr), 2023, 46(3):545-570. doi: 10.1007/s13402-023-00777-x.
[10]	Sun X, Ye G, Li J, et al. The tumor suppressor Parkin exerts anticancer effects through regulating mitochondrial GAPDH activity[J]. Oncogene, 2024, 43(44):3215-3226. doi: 10.1038/s41388-024-03157-3. pmid: 39285229
[11]	Wang S, Qiao X, Cui Y, et al. NCAPH, ubiquitinated by TRIM21, promotes cell proliferation by inhibiting autophagy of cervical cancer through AKT/mTOR dependent signaling[J]. Cell Death Dis, 2024, 15(8):565. doi: 10.1038/s41419-024-06932-y. pmid: 39103348
[12]	Lin M, Zhang J, Bouamar H, et al. Fbxo22 promotes cervical cancer progression via targeting p57(Kip2) for ubiquitination and degradation[J]. Cell Death Dis, 2022, 13(9):805. doi: 10.1038/s41419-022-05248-z.
[13]	Cai H, Zhang F, Li Z. Gfi-1 promotes proliferation of human cervical carcinoma via targeting of FBW7 ubiquitin ligase expression[J]. Cancer Manag Res, 2018, 10:2849-2857. doi: 10.2147/CMAR.S161130. pmid: 30197537
[14]	Fontana R, Mestre-Farrera A, Yang J. Update on Epithelial-Mesenchymal Plasticity in Cancer Progression[J]. Annu Rev Pathol, 2024,19:133-156. doi: 10.1146/annurev-pathmechdis-051222-122423.
[15]	Wang X, De Geyter C, Jia Z, et al. HECTD1 regulates the expression of SNAIL: Implications for epithelial-mesenchymal transition[J]. Int J Oncol, 2020, 56(5):1186-1198. doi: 10.3892/ijo.2020.5002.
[16]	Li S, Shi L, Wang Y, et al. FBXO22 inhibits proliferation and metastasis of cervical cancer cells by mediating ubiquitination-dependent degradation of GAK[J]. Exp Cell Res, 2023, 430(1):113719. doi: 10.1016/j.yexcr.2023.113719.
[17]	Pang K, Lee J, Kim J, et al. Degradation of DRAK1 by CUL3/SPOP E3 Ubiquitin ligase promotes tumor growth of paclitaxel-resistant cervical cancer cells[J]. Cell Death Dis, 2022, 13(2):169. doi: 10.1038/s41419-022-04619-w. pmid: 35194034
[18]	Atri Y, Bharti H, Sahani N, et al. CUL4A silencing attenuates cervical carcinogenesis and improves Cisplatin sensitivity[J]. Mol Cell Biochem, 2024, 479(5):1041-1058. doi: 10.1007/s11010-023-04776-2.
[19]	Song Q, Wen J, Li W, et al. HSP90 promotes radioresistance of cervical cancer cells via reducing FBXO6-mediated CD147 polyubiquitination[J]. Cancer Sci, 2022, 113(4):1463-1474. doi: 10.1111/cas.15269.
[20]	Grau-Bejar JF, Garcia-Duran C, Garcia-Illescas D, et al. Advances in immunotherapy for cervical cancer[J]. Ther Adv Med Oncol, 2023,15:17588359231163836. doi: 10.1177/17588359231163836.
[21]	Niebler M, Qian X, Höfler D, et al. Post-translational control of IL-1β via the human papillomavirus type 16 E6 oncoprotein: a novel mechanism of innate immune escape mediated by the E3-ubiquitin ligase E6-AP and p53[J]. PLoS Pathog, 2013, 9(8):e1003536. doi: 10.1371/journal.ppat.1003536.
[22]	Gazzaroli G, Angeli A, Giacomini A, et al. Proteasome inhibitors as anticancer agents[J]. Expert Opin Ther Pat, 2023, 33(11):775-796. doi: 10.1080/13543776.2023.2272648.
[23]	Bhattacharjee R, Das SS, Biswal SS, et al. Mechanistic role of HPV-associated early proteins in cervical cancer: Molecular pathways and targeted therapeutic strategies[J]. Crit Rev Oncol Hematol, 2022,174:103675. doi: 10.1016/j.critrevonc.2022.103675.
[24]	Makgoo L, Mosebi S, Mbita Z. Molecular Mechanisms of HIV Protease Inhibitors Against HPV-Associated Cervical Cancer: Restoration of TP53 Tumour Suppressor Activities[J]. Front Mol Biosci, 2022,9:875208. doi: 10.3389/fmolb.2022.875208.
[25]	Zhang Q, Song J, Cao L, et al. RNF113A targeted by miR-197 promotes proliferation and inhibits autophagy via CXCR4/CXCL12/AKT/ERK/Beclin1 axis in cervical cancer[J]. Exp Cell Res, 2023, 428(1):113632. doi: 10.1016/j.yexcr.2023.113632.
[26]	Kenny S, Iyer S, Gabel CA, et al. Structure of E6AP in complex with HPV16-E6 and p53 reveals a novel ordered domain important for E3 ligase activation[J]. Structure, 2025, 33(3):504-516.e4. doi: 10.1016/j.str.2024.12.013.
[27]	Patiño-Morales CC, Soto-Reyes E, Arechaga-Ocampo E, et al. Curcumin stabilizes p53 by interaction with NAD(P)H:quinone oxidoreductase 1 in tumor-derived cell lines[J]. Redox Biol, 2020,28:101320. doi: 10.1016/j.redox.2019.101320.
[28]	Vats A, Braga L, Kavcic N, et al. Regulation of human papillomavirus E6 oncoprotein function via a novel ubiquitin ligase FBXO4[J]. mBio, 2025, 16(2):e0278324. doi: 10.1128/mbio.02783-24.
[29]	Peuget S, Zhou X, Selivanova G. Translating p53-based therapies for cancer into the clinic[J]. Nat Rev Cancer, 2024, 24(3):192-215. doi: 10.1038/s41568-023-00658-3.
[30]	Zhang J, Yu G, Yang Y, et al. A small-molecule inhibitor of MDMX suppresses cervical cancer cells via the inhibition of E6-E6AP-p53 axis[J]. Pharmacol Res, 2022,177:106128. doi: 10.1016/j.phrs.2022.106128.
[31]	Sobierajski T, Małolepsza J, Pichlak M, et al. The impact of E3 ligase choice on PROTAC effectiveness in protein kinase degradation[J]. Drug Discov Today, 2024, 29(7):104032. doi: 10.1016/j.drudis.2024.104032.
[32]	Sakamoto KM, Kim KB, Kumagai A, et al. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation[J]. Proc Natl Acad Sci U S A, 2001, 98(15):8554-8559. doi: 10.1073/pnas.141230798.
[33]	Sakamoto KM, Kim KB, Verma R, et al. Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation[J]. Mol Cell Proteomics, 2003, 2(12):1350-1358. doi: 10.1074/mcp.T300009-MCP200. pmid: 14525958
[34]	Shi YY, Dong DR, Fan G, et al. A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells[J]. Front Immunol, 2023,14:1237964. doi: 10.3389/fimmu.2023.1237964.
[35]	Smalley TB, Nicolaci A, Tran KC, et al. Targeted degradation of the HPV oncoprotein E6 reduces tumor burden in cervical cancer[J]. bioRxiv, 2024:2024.10.17.618959. doi: 10.1101/2024.10.17.618959.
[36]	Yao Y, Wu M, Wang Y, et al. An Oral PROTAC Targeting HPK1 Degradation Potentiates Anti-Solid Tumor Immunity[J]. Adv Mater, 2025, 37(3):e2411454. doi: 10.1002/adma.202411454.
[37]	Liu Y, Bai J, Li D, et al. Routes to molecular glue degrader discovery[J]. Trends Biochem Sci, 2025, 50(2):134-142. doi: 10.1016/j.tibs.2024.12.006. pmid: 39753433
[38]	Lu P, Cheng Y, Xue L, et al. Selective degradation of multimeric proteins by TRIM21-based molecular glue and PROTAC degraders[J]. Cell, 2024, 187(25):7126-7142.e20. doi: 10.1016/j.cell.2024.10.015. pmid: 39488207
[39]	Zhang D, Lin P, Lin J. Molecular glues targeting GSPT1 in cancers: A potent therapy[J]. Bioorg Chem, 2024,143:107000. doi: 10.1016/j.bioorg.2023.107000.